About Endo Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
On , Mallinckrodt and Endo joined together to better serve patients and customers with a bold plan for the future. Following the merger, the combined company then spun off its generics and sterile injectables business as an independent company—Par Health—and rebranded the specialty therapeutics company as Keenova Therapeutics in November 2025.
DUBLIN, Aug. 1, 2025 / PRNewswire / -- Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics leader. "We are excited to pursue a promising new future for all the stakeholders of Mallinckrodt and Endo," said Siggi Olafsson, President and Chief Executive Officer of the combined company. "We commend the employees ...
Experienced and Highly Capable Senior Executives to Lead both the Branded Specialty Pharmaceutical and Generics & Sterile Injectables Businesses Generics & Sterile Injectables Spin-Off to be Called Par Health DUBLIN and MALVERN, Pa., – Mallinckrodt plc (“Mallinckrodt”) and Endo, Inc. (OTCQX: NDOI) (“Endo”) today announced the future executive team that will drive the ...
As announced on , the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into a new standalone entity separate from the remaining branded pharmaceuticals business.
Endo’s board of directors oversees and advises our leaders to protect the long-term interests of the company and our shareholders. The experienced and independent board members are committed to building sustainable success.